Actuate Therapeutics, Inc. ACTU 深 沪
已收盘 01-30 16:00:00 美东时间
4.71
-0.030
-0.63%
华盛通- 最 高4.86
- 今 开4.70
- 成交量 6.09万股
- 最 低 4.57
- 昨 收 4.74
- 总市值 1.08亿
- 52周最高 11.99
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 4.57
- 委 比 -77.78%
- 总股本 2292.19万
- 历史最高 11.99
- 量 比 0.58
- 振 幅 6.12%
- 历史最低 4.57
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage Form Of Elraglusib In Patients With Advanced Cancer
Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the
01-21 21:51
Actuate Announces Results From Phase 1 Portion Of Phase 1/2 Clinical Study Evaluating Elraglusib As Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic
01-06 21:47
Actuate Therapeutics Announces Publication Of New Data In Clinical Cancer Research From A Phase II Study; Reports Phase II Results Of Elraglusib With Platinum Chemotherapy Shows Median Survival Of 18.6 Months In Refractory Salivary Gland Cancer
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β expression may help identify patientsmost likely to respond to treatment of a
2025-12-15 21:49
Actuate Therapeutics Signs $100M Sales Agreement
An update from Actuate Therapeutics, Inc. ( ($ACTU) ) is now available. On Nove...
2025-11-29 06:48
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $20 price target.
2025-11-19 19:32
Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate
Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.07 percent. This is a 54.55 percent increase over losses of $(0.55) per share
2025-11-14 06:44
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
2025-09-24 10:23
Actuate Therapeutics Advances Elraglusib As Potential Backbone Therapy For Pancreatic Cancer With Phase 2 Data Supporting Upcoming FDA And EMA Submissions
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
2025-09-22 20:47
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Actuate Therapeutics announced positive findings for elraglusib, a GSK-3β inhibitor, showing improved survival in metastatic pancreatic cancer when combined with gemcitabine/nab-paclitaxel (GnP). The Phase 2 trial demonstrated a statistically significant increase in median overall survival, with a 37% reduction in death risk and doubled 12-month survival rate. The company secured $17.25 million to advance regulatory submissions and further studie...
2025-09-22 12:45
